Cite
Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19.
MLA
Garcia-Vidal, Carolina, et al. “Impact of Remdesivir According to the Pre-Admission Symptom Duration in Patients with COVID-19.” The Journal of Antimicrobial Chemotherapy, vol. 76, no. 12, Nov. 2021, pp. 3296–302. EBSCOhost, https://doi.org/10.1093/jac/dkab321.
APA
Garcia-Vidal, C., Alonso, R., Camon, A. M., Cardozo, C., Albiach, L., Agüero, D., Marcos, M. A., Ambrosioni, J., Bodro, M., Chumbita, M., de la Mora, L., Garcia-Pouton, N., Dueñas, G., Hernandez-Meneses, M., Inciarte, A., Cuesta, G., Meira, F., Morata, L., Puerta-Alcalde, P., … Soriano, A. (2021). Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19. The Journal of Antimicrobial Chemotherapy, 76(12), 3296–3302. https://doi.org/10.1093/jac/dkab321
Chicago
Garcia-Vidal, Carolina, Rodrigo Alonso, Ana M Camon, Celia Cardozo, Laia Albiach, Daiana Agüero, M Angeles Marcos, et al. 2021. “Impact of Remdesivir According to the Pre-Admission Symptom Duration in Patients with COVID-19.” The Journal of Antimicrobial Chemotherapy 76 (12): 3296–3302. doi:10.1093/jac/dkab321.